Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats

Table 3 Hemodynamic data of rats

	Sham		BDL		P
	Placebo n = 9	V-PYRRO/NO n = 12	Placebo n = 12	V-PYRRO/NO n = 10
MAP (mm Hg)	119 ± 7	113 ± 11	104 ± 8a	98 ± 13b	< 0.001
Heart rate (beat/min)	441 ± 29	428 ± 44	411 ± 29	422 ± 26	NS
Cardiac index (mL/min .100 g)	14 ± 5	15 ± 4	39 ± 11a	33 ± 6ac	< 0.0001
SVR (dyn.s.cm5.100 g1.103)	782 ± 355	636 ± 184	236 ± 89a	248 ± 78c	< 0.0001
Portal pressure (mmHg)	9.2 ± 0.8	8.0 ± 1.2	16.3 ± 2.2a	11.9 ± 2.7ace	< 0.0001
SRS BF (mL/min)	0.22 ± 0.08	0.31 ± 0.12	1.33 ± 1.34a	0.42 ± 0.22e	0.007

^aP < 0.05 vs Sham,

^cP < 0.05 vs sham V-PYRRO/NO,

^eP < 0.05 vs BDL placebo. MAP: Mean arterial pressure, SRS BF: Spleno-renal shunt blood flow; SVR: Systemic vascular resistance; NS: Not significant.